Lin H C, Hou M C, Lee W C, Huang Y T, Lee F Y, Chang F Y, Tsai Y T, Lee S D
Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taiwan, ROC.
Am J Gastroenterol. 1999 Apr;94(4):1012-7. doi: 10.1111/j.1572-0241.1999.01005.x.
Octreotide has potentially beneficial effects in patients with cirrhosis. However, the effects of octreotide on central hemodynamics and oxygen use have not been established. The present study was undertaken to evaluate the effect of octreotide on central hemodynamics and oxygen use in patients with viral cirrhosis.
Twenty-five patients with cirrhosis were enrolled in the study. They were randomly assigned to receive either placebo (n = 10) or a continuous infusion of 100 microg/h of octreotide after an initial 100-microg bolus (n = 15). Hemodynamic measurements and oxygenation values were obtained before and 60 min after octreotide or placebo administration.
Placebo administration did not have any effect on hemodynamic and oxygenation values. In patients who received octreotide, systemic hemodynamic values including cardiac index, mean arterial pressure, and systemic vascular resistance were not affected. The mean pulmonary arterial pressure tended to increase after octreotide administration but was statistically insignificant. There was a significant increase in pulmonary arterial vascular resistance, whereas the pulmonary capillary wedge pressure and right atrial pressure were significantly decreased. Arterial oxygen tension, systemic oxygen uptake, and oxygen extraction ratio were significantly decreased after octreotide administration, whereas oxygen transport as well as arterial and mixed venous oxygen contents remained unchanged.
In patients with viral cirrhosis, octreotide administration exerted a significant effect on pulmonary circulation. It also resulted in a decrease in systemic oxygen uptake and oxygen extraction ratio. These results suggested that octreotide may impair tissue oxygenation in patients with viral cirrhosis.
奥曲肽对肝硬化患者可能具有有益作用。然而,奥曲肽对中心血流动力学和氧利用的影响尚未明确。本研究旨在评估奥曲肽对病毒性肝硬化患者中心血流动力学和氧利用的影响。
25例肝硬化患者纳入本研究。他们被随机分为两组,一组接受安慰剂(n = 10),另一组在初始静脉推注100微克奥曲肽后,以100微克/小时的速度持续输注奥曲肽(n = 15)。在给予奥曲肽或安慰剂之前及之后60分钟测量血流动力学参数和氧合值。
给予安慰剂对血流动力学和氧合值无任何影响。接受奥曲肽的患者中,包括心脏指数、平均动脉压和全身血管阻力在内的全身血流动力学参数未受影响。奥曲肽给药后平均肺动脉压有升高趋势,但无统计学意义。肺动脉血管阻力显著增加,而肺毛细血管楔压和右心房压显著降低。奥曲肽给药后动脉血氧分压、全身氧摄取量和氧摄取率显著降低,而氧输送以及动脉血氧含量和混合静脉血氧含量保持不变。
在病毒性肝硬化患者中,奥曲肽给药对肺循环有显著影响。它还导致全身氧摄取量和氧摄取率降低。这些结果表明奥曲肽可能损害病毒性肝硬化患者的组织氧合。